Teva announces launch of generic VESIcare® (solifenacin succinate) tabletsin the U.S.
Teva announced the launch of a generic version of VESIcare® (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S. Solifenacin Succinate Tablets are a muscarinic antagonist indicated for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. April 22, 2019